NR3C2 and diabetic kidney disease: Although large-scale clinical trials specifically targeting therapies for DKD are lacking, the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial has indicated that DKD patients derive greater benefit from anti-inflammatory treatment with Finerenone, a first novel, highly potent, selective mineralocorticoid receptor antagonist (63).